Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06203106 | NYSCF Scientific Discovery Biobank | recruiting | — | 10,000 | New York Stem Cell Foundation Research InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT00005095 | Specimen and Data Study for Ovarian Cancer Early Detection and Prevention | recruiting | — | 6,000 | Northwestern UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06844136 | ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients(ChemoINtel) | recruiting | — | 100 | Pierian BiosciencesINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06836219 | Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario(BeLIVE) | recruiting | — | 300 | Consorzio OncotechOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827353 | Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency(OVNI-B) | recruiting | — | 300 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04282356 | Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer(INTENS-IP) | recruiting | Phase 2 | 55 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06084195 | Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging(MR-O-MICS) | recruiting | N/A | 120 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05200260 | Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | recruiting | Phase 2 | 220 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800612 | Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers | recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06392997 | Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology(GynRNA) | recruiting | — | 2,500 | ZIWIGINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06785077 | Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors | recruiting | N/A | 157 | European Institute of OncologyOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04846933 | Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC(DECIDER) | recruiting | N/A | 200 | Turku University HospitalOTHER_GOV | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06775470 | Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer | recruiting | — | 300 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06777082 | Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma(OVCAR) | recruiting | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06760923 | Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression | recruiting | — | 240 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06751303 | Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's(4PDQ) | recruiting | N/A | 100 | University of SaskatchewanOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05855941 | Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)(PRODIGYN) | recruiting | — | 120 | Region VästerbottenOTHER_GOV | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735326 | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | recruiting | Phase 2 | 105 | Qilu Hospital of Shandong UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health(COACH) | recruiting | N/A | 625 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06437353 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | recruiting | Phase 2 | 74 | Anhui Provincial Cancer HospitalOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT05927818 | Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer | recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT02754115 | An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | recruiting | — | 400 | Tata Memorial CentreOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT06614790 | Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.(NIRAPARIB) | recruiting | — | 300 | Pomeranian Medical University SzczecinOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04921527 | Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer(CHIPRO) | recruiting | Phase 3 | 454 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06638593 | MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm.(MIRRORS-FROZEN) | recruiting | N/A | 40 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06640348 | Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer | recruiting | — | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06284343 | The Gynecological Cancer Associated Thrombosis (GynCAT) Study(GynCAT) | recruiting | — | 1,800 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04665635 | Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery | recruiting | N/A | 120 | Cukurova UniversityOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06014190 | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | recruiting | Phase 2 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06378905 | Cukurova Score Validation Study(CUKUROVA) | recruiting | — | 130 | Cukurova UniversityOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT01970696 | International Ovarian & Testicular Stromal Tumor Registry(OTST) | recruiting | — | 300 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06394492 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | recruiting | Phase 3 | 440 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05410717 | CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors | recruiting | Phase 1 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06216496 | Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer(AMINOCANCER) | recruiting | N/A | 23 | University Hospital, GrenobleOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06420973 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | recruiting | Phase 2 | 54 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05842629 | Improved Diagnosis of Ovarian Cancer | recruiting | — | 1,700 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06404671 | Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer | recruiting | N/A | 250 | Alexandria UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06251947 | Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06395844 | Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06272240 | Tumor Microenvironment in Ovarian Cancer(MICO) | recruiting | — | 50 | University of UdineOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05983276 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | recruiting | Phase 2 | 40 | Loyola UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 3, 2025source: clinicaltrials